PCN123 BUDGET IMPACT ANALYSIS OF FIRST-LINE RIBOCICLIB IN THE TREATMENT OF PRE- AND POST-MENOPAUSAL WOMEN WITH HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER IN THE UNITED STATES